Cited by 399Diabetes Treatment and ManagementDiabetes Management and ResearchPharmacology and Obesity Treatment

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

Komoroski, B, Vachharajani, N, Feng, Y, Li, L, Kornhauser, D, Pfister, M·2009·Clinical Pharmacology & Therapeutics

DOI 10.1038/clpt.2008.250

Open this paper in CoChat — free account

Abstract

Dapagliflozin, administered to patients in once-daily oral doses, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks the reabsorption of glucose from urine into the blood. This 14-day study randomized patients with type 2 diabetes mellitus (T2DM) to four treatment groups receiving daily oral doses of 5-, 25-, or 100-mg doses of dapagliflozin or placebo, in order to evaluate glucosuria and glycemic parameters. Significant reductions in fasting serum glucose (FSG) were observed on day 2 with 100 mg dapagliflozin (-9.3%, P < 0.001), and dose-dependent reductions were observed on day 13 with the 5-mg (-11.7%; P < 0.05), 25-mg (-13.3%; P < 0.05), and 100-mg (-21.8%; P < 0.0001) doses as compared with placebo. Significant improvements in oral glucose tolerance test (OGTT) were observed with all doses on days 2 and 13 (P < 0.001 as compared with placebo). On day 14, urine glucose values were 36.6, 70.1, and 69.9 g/day for the 5-, 25-, and 100-mg doses (as compared with no change for placebo), which were slightly lower than those on day 1. This was attributed to the decrease in filtered glucose load following improved glycemic control. Dapagliflozin produced dose-dependent increases in glucosuria and clinically meaningful changes in glycemic parameters in T2DM patients.

Integrity signals

Registry

Crossref · 10.1038/clpt.2008.250

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.
Rossetti, L., Smith, D. J., Shulman, G. I., Papachristou, D. N., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 824
Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634
Active sugar transport in health and disease
Wright, E. M., Hirayama, B. A., & Loo, D. F. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01746.x · Cited by 627
Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats
Han, S., Hagan, D. L., Taylor, J. R., Xin, L., Meng, W., Biller, S. A., Wetterau, J. R., Washburn, W. N., & Whaley, J. M. (2008) · Diabetes · doi:10.2337/db07-1472 · Cited by 423
Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria
Santer, R., Kinner, M., Lassen, C. L., Schneppenheim, R., Eggert, P., Bald, M., Brodehl, J., Daschner, M., Ehrich, J. H. H., Kemper, M., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000092790.89332.d2 · Cited by 304
Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose Level
Katsuno, K., Fujimori, Y., Takemura, Y., Hiratochi, M., Itoh, F., Komatsu, Y., Fujikura, H., & Isaji, M. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110296 · Cited by 268
Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal
Andrews, W. J., Vasquez, B., NAGULESPARAN, M., Klimeś, I., Foley, J. E., Unger, R. H., & Reaven, G. M. (1984) · Diabetes · doi:10.2337/diab.33.7.634 · Cited by 194
Candidal Vulvovaginitis
Sobel, J. D. (1993) · Clinical Obstetrics & Gynecology · doi:10.1097/00003081-199303000-00021 · Cited by 154
Long-term outcome of renal glucosuria type 0: the original patient and his natural history
Scholl‐Bürgi, S., Santer, R., & Ehrich, J. H. H. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh366 · Cited by 104

Flagged first, then by citations

Show all 20 references

Research works printed but not linked: 3

Chen J, 2008, Diabetes, 57, A682
Oemar B.S, 1987, Clin. Nephrol, 27, 156
Gibb D, 1995, NZ Med. J, 108, 252

Sorted by citations

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 873
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
SGLT2 inhibition — a novel strategy for diabetes treatment
Chao, E. C., & Henry, R. R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3180 · Cited by 834
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Hopkins, B. D., Pauli, C., Du, X., Wang, D. G., Li, X., Wu, D., Amadiume, S. C., Goncalves, M. D., Hodakoski, C., Lundquist, M. R., et al. (2018) · Nature · doi:10.1038/s41586-018-0343-4 · Cited by 706
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 725
Inhibition of the Glucose Transporter SGLT2 with Dapagliflozin in Pancreatic Alpha Cells Triggers Glucagon Secretion
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
DeFronzo, R. A., Norton, L., & Abdul‐Ghani, M. A. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.170 · Cited by 588
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin
Nauck, M. A., Prato, S. D., Meier, J. J., Durán-Garcia, S., Rohwedder, K., Elze, M., & Parikh, S. J. (2011) · Diabetes Care · doi:10.2337/dc11-0606 · Cited by 535
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
DeFronzo, R. A., Davidson, J. A., & Prato, S. D. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01511.x · Cited by 497
Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin
Wilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., Parikh, S., & for the Dapagliflozin 006 Study Group* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-6-201203200-00003 · Cited by 478
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ferrannini, E., & Solini, A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.243 · Cited by 466
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul‐Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 454
Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
Rosenstock, J., Vico, M. L., Wei, L., Salsali, A., & List, J. F. (2012) · Diabetes Care · doi:10.2337/dc11-1693 · Cited by 416
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial
Strojek, K., Yoon, K., Hrubá, V., Elze, M., Langkilde, A. M., & Parikh, S. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01434.x · Cited by 410
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Inzucchi, S. E., Zinman, B., Wanner, C., Ferrari, R., FITCHETT, D. H., Hantel, S., Espadero, R.-M., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114559852 · Cited by 409
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Heerspink, H. J. L., Kosiborod, M., Inzucchi, S. E., & Cherney, D. Z. I. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.027 · Cited by 393
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
van Bommel, E. J. M., Muskiet, M. H. A., van Baar, M. J. B., Tonneijck, L., Smits, M. M., Emanuel, A. L., Bozovic, A., Danser, A. H. J., Geurts, F., Hoorn, E. J., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.013 · Cited by 363
A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers
Wilding, J. P. H., Norwood, P. C., T'joen, C., Bastien, A., List, J. F., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc09-0517 · Cited by 365
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
Bailey, C. J., Gross, J. L., Hennicken, D., Iqbal, N., Mansfield, T. A., & List, J. F. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-43 · Cited by 356
Familial Renal Glucosuria and SGLT2
Santer, R., & Calado, J. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04010609 · Cited by 347
SGLT inhibitors in management of diabetes
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70050-0 · Cited by 344
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes
DeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., Morrow, L. A., Leslie, B. R., Boulton, D. W., Ching, A., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0387 · Cited by 293
Self-citation
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years
Wilding, J. P. H., Woo, V. C., Rohwedder, K., Sugg, J. E., Parikh, S. J., & for the Dapagliflozin 006 Study Group (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12187 · Cited by 290
The molecular mechanisms of pancreatic β-cell glucotoxicity: Recent findings and future research directions
Bensellam, M., Laybutt, D. R., & Jonas, J. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.003 · Cited by 304
A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.560181 · Cited by 284
The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet
Han, J. H., Oh, T. J., Lee, G., Maeng, H. J., Lee, D. H., Kim, K. M., Choi, S. H., Jang, H. C., Lee, H. S., Park, K. S., et al. (2017) · Diabetologia · doi:10.1007/s00125-016-4158-2 · Cited by 281
Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2
Kasichayanula, S., Liu, X., LaCreta, F., Griffen, S. C., & Boulton, D. W. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0104-3 · Cited by 276
Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria
Geerlings, S. E., Fonseca, V. A., Castro-Diaz, D. M., List, J. F., & Parikh, S. J. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.12.052 · Cited by 280
Glucose transport by human renal Na + / d -glucose cotransporters SGLT1 and SGLT2
Hummel, C. S., Lü, C., Loo, D. D. F., Hirayama, B. A., Voss, A. A., & Wright, E. M. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00388.2010 · Cited by 273
Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure
Byrne, N. J., Matsumura, N., Maayah, Z. H., Ferdaoussi, M., Takahara, S., Darwesh, A. M., Levasseur, J. L., Jahng, J. W. S., Vos, D. Y., Parajuli, N., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.119.006277 · Cited by 265
LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial
Zambrowicz, B., Freiman, J., Brown, P., Frazier, K., Turnage, A., Bronner, J., Ruff, D. S., Shadoan, M. K., Banks, P. L., Mseeh, F., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.58 · Cited by 251
Dapagliflozin: A Review in Type 2 Diabetes
Dhillon, S. (2019) · Drugs · doi:10.1007/s40265-019-01148-3 · Cited by 264
Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development
Milligan, P. A., Brown, M. J., Marchant, B., Martin, S. W., van der Graaf, P. H., Benson, N., Nucci, G., Nichols, D. J., Boyd, R. A., Mandema, J. W., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.54 · Cited by 238
Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
Henry, R. R., Rosenstock, J., Edelman, S. V., Mudaliar, S. R., Chalamandaris, A.-G., Kasichayanula, S., Bogle, A., Iqbal, N., List, J. F., & Griffen, S. C. (2014) · Diabetes Care · doi:10.2337/dc13-2955 · Cited by 238
SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome
van Bommel, E. J. M., Muskiet, M. H. A., Tonneijck, L., Kramer, M. H. H., Nieuwdorp, M., & van Raalte, D. H. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06080616 · Cited by 226
SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
Jurczak, M. J., Lee, H., Birkenfeld, A. L., Jornayvaz, F. R., Frederick, D. W., Pongratz, R. L., Zhao, X., Moeckel, G. W., Samuel, V. T., Whaley, J. M., et al. (2011) · Diabetes · doi:10.2337/db10-1328 · Cited by 221
Renal glucose reabsorption inhibitors to treat diabetes
Bailey, C. J. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.011 · Cited by 218
Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet‐Induced Obese (DIO) Rats
Devenny, J. J., Godonis, H. E., Harvey, S. J., Rooney, S., Cullen, M. J., & Pelleymounter, M. A. (2012) · Obesity · doi:10.1038/oby.2012.59 · Cited by 212
Urinary tract infections in patients with diabetes treated with dapagliflozin
Johnsson, K. M., Ptaszynska, A., Schmitz, B., Sugg, J. E., Parikh, S. J., & List, J. F. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.05.004 · Cited by 207
Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies
Prato, S. D. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02847.x · Cited by 207
Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
Heerspink, H. J. L., JOHNSSON, E. K., Gause‐Nilsson, I. A. M., Cain, V. A., & Sjöström, C. D. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12654 · Cited by 191
Glycaemic control in type 2 diabetes: Targets and new therapies
Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 190
LX4211 Increases Serum Glucagon-Like Peptide 1 and Peptide YY Levels by Reducing Sodium/Glucose Cotransporter 1 (SGLT1)–Mediated Absorption of Intestinal Glucose
Powell, D. R., Smith, M. G., Greer, J., Harris, A. L., Zhao, S., DaCosta, C. M., Mseeh, F., Shadoan, M. K., Sands, A., Zambrowicz, B., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203364 · Cited by 189
The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer
Koepsell, H. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.017 · Cited by 189
In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans
Obermeier, M. T., Yao, M., Khanna, A., Koplowitz, B., Zhu, M. J., Li, W., Komoroski, B. J., Kasichayanula, S., Discenza, L., Washburn, W., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029165 · Cited by 187
Self-citation
Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
List, J. F., & Whaley, J. M. (2011) · Kidney International · doi:10.1038/ki.2010.512 · Cited by 184
Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24‐Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study with a 28‐Week Extension
Leiter, L. A., Cefalu, W. T., de Bruin, T. W., Gause‐Nilsson, I. A. M., Sugg, J. E., & Parikh, S. J. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12881 · Cited by 183
SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
Karg, M. V., Bosch, A., Kannenkeril, D., Striepe, K., Ott, C., Schneider, M. P., Boemke-Zelch, F., Linz, P. R., Nagel, A. M., Titze, J. M., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0654-z · Cited by 188
The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis
Cai, X., Yang, W., Gao, X., Chen, Y., Zhou, L., Zhang, S., Han, X., & Ji, L. (2018) · Obesity · doi:10.1002/oby.22066 · Cited by 181
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Bansilal, S., Bhatt, D. L., Leiter, L. A., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.01.012 · Cited by 186
Discovery of Tofogliflozin, a Novel C-Arylglucoside with an O-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Ohtake, Y., Sato, T., Kobayashi, T., Nishimoto, M., Taka, N., Takano, K., Yamamoto, K., Ohmori, M., Yamaguchi, M., Takami, K., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300884k · Cited by 174
Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System
Ansary, T. M., Nakano, D., & Nishiyama, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030629 · Cited by 174
SGLT2 inhibitors in the treatment of type 2 diabetes
Hasan, F., Alsahli, M., & Gerich, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.02.014 · Cited by 180
Dapagliflozin as Monotherapy in Drug-Naive Asian Patients With Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III Study
Ji, L., Ma, J., Li, H., Mansfield, T. A., T'joen, C., Iqbal, N., Ptaszynska, A., & List, J. F. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.11.002 · Cited by 174
Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
Zhang, L., Feng, Y., List, J. F., Kasichayanula, S., & Pfister, M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01216.x · Cited by 167
Self-citation
The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors
Wilding, J. P. H. (2014) · Metabolism · doi:10.1016/j.metabol.2014.06.018 · Cited by 176
Dapagliflozin monotherapy in drug‐naïve patients with diabetes: a randomized‐controlled trial of low‐dose range
Bailey, C. J., Iqbal, N., T'joen, C., & List, J. F. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01659.x · Cited by 171
Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus
Abdul‐Ghani, M. A., Norton, L., & DeFronzo, R. A. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00267.2015 · Cited by 172
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
Marx, N., & McGuire, D. K. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw110 · Cited by 166
Improved glycemic control in mice lacking Sglt1 and Sglt2
Powell, D. R., DaCosta, C. M., Gay, J. P., Ding, Z., Smith, M. G., Greer, J., Doree, D. D., Jeter-Jones, S. L., Mseeh, F., Rodriguez, L. A., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00439.2012 · Cited by 161
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials
Jabbour, S. A., Seufert, J., Scheen, A. J., Bailey, C. J., Karup, C., & Langkilde, A. M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13124 · Cited by 161
Sodium-Glucose Co-Transport Inhibitors
Neumiller, J. J., White, J. R., & Campbell, R. K. (2010) · Drugs · doi:10.2165/11318680-000000000-00000 · Cited by 156
Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double‐blind placebo‐controlled 102‐week trial
Bailey, C. J., Villegas, E. C. M., Woo, V. C., Tang, W., Ptaszynska, A., & List, J. F. (2014) · Diabetic Medicine · doi:10.1111/dme.12624 · Cited by 153
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects
Tahara, A., Takasu, T., Yokono, M., Imamura, M., & Kurosaki, E. (2016) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.02.003 · Cited by 148
Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects
Wilcox, C. S., Shen, W., Boulton, D. W., Leslie, B. R., & Griffen, S. C. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007046 · Cited by 139
Ipragliflozin and other sodium–glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data
Kurosaki, E., & Ogasawara, H. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.04.003 · Cited by 136
Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double‐blind, placebo‐controlled trial
Kaku, K., Inoue, S., Matsuoka, O., Kiyosue, A., Azuma, H., Hayashi, N., Tokudome, T., Langkilde, A. M., & Parikh, S. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12047 · Cited by 135
Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years
Liu, X., Zhang, N., Chen, R., Zhao, J., & Yu, P. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.07.011 · Cited by 137
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents
Choi, C. (2016) · Molecules · doi:10.3390/molecules21091136 · Cited by 136
The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus
Kasichayanula, S., Liu, X., Benito, M. P., Yao, M., Pfister, M., LaCreta, F. P., Humphreys, W. G., & Boulton, D. W. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12056 · Cited by 121
Self-citation
Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
Abdul‐Ghani, M. A., Norton, L., & DeFronzo, R. A. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0275-6 · Cited by 123
Expansion of the Homeostasis Model Assessment of β-Cell Function and Insulin Resistance to Enable Clinical Trial Outcome Modeling Through the Interactive Adjustment of Physiology and Treatment Effects: iHOMA2
Hill, N., Levy, J., & Matthews, D. (2013) · Diabetes Care · doi:10.2337/dc12-0607 · Cited by 123
Energy balance and metabolic changes with sodium‐glucose co‐transporter 2 inhibition
Rajeev, S. P., Cuthbertson, D. J., & Wilding, J. P. H. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12578 · Cited by 117
Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co‐transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus
Kasichayanula, S., Chang, M., Hasegawa, M., Liu, X., Yamahira, N., LaCreta, F. P., Imai, Y., & Boulton, D. W. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01359.x · Cited by 117
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin
Nauck, M. A., Prato, S. D., Durán-Garcia, S., Rohwedder, K., Langkilde, A. M., Sugg, J. E., & Parikh, S. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12327 · Cited by 114
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0713-z · Cited by 110
A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium‐glucose co‐transporter‐2 inhibitors
Brown, E. E., Rajeev, S. P., Cuthbertson, D. J., & Wilding, J. P. H. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13650 · Cited by 107
SGLT2 inhibitors: molecular design and potential differences in effect
Isaji, M. (2011) · Kidney International · doi:10.1038/ki.2010.511 · Cited by 104
Apple Trees to Sodium Glucose Co-Transporter Inhibitors: A Review of SGLT2 Inhibition
White, J. R. (2010) · Clinical Diabetes · doi:10.2337/diaclin.28.1.5 · Cited by 106
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter‐2 Inhibitors in Adults with Type 2 Diabetes Mellitus
Taylor, S. R., & Harris, K. B. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1303 · Cited by 103
Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
Kashiwagi, A., Kazuta, K., Yoshida, S., & Nagase, I. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12156 · Cited by 100
Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes
Verspohl, E. J. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003319 · Cited by 102
Genital Infections with Sodium Glucose Cotransporter-2 Inhibitors: Occurrence and Management in Patients with Type 2 Diabetes Mellitus
Unnikrishnan, A., Kalra, S., Purandare, V. B., & Vasnawala, H. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_159_17 · Cited by 100
Dapagliflozin
Plosker, G. L. (2012) · Drugs · doi:10.2165/11209910-000000000-00000 · Cited by 99
Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models
Suzuki, M., Takeda, M., Kito, A., Fukazawa, M., Yata, T., Yamamoto, M., Nagata, T., Fukuzawa, T., Yamane, M., Honda, K., et al. (2014) · Nutrition and Diabetes · doi:10.1038/nutd.2014.20 · Cited by 97
Bromocriptine – unique formulation of a dopamine agonist for the treatment of type 2 diabetes
Scranton, R. E., & Cincotta, A. H. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903501544 · Cited by 96
Structural selectivity of human SGLT inhibitors
Hummel, C. S., Lü, C., Liu, J., Ghezzi, C., Hirayama, B. A., Loo, D. D. F., Kepe, V., Barrio, J. R., & Wright, E. M. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00328.2011 · Cited by 94
Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study
Kasichayanula, S., Liu, X., Zhang, W., Pfister, M., LaCreta, F. P., & Boulton, D. W. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.09.011 · Cited by 94
Self-citation
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects
Kasichayanula, S., Liu, X., Shyu, W. C., Zhang, W., Pfister, M., Griffen, S. C., Li, T., LaCreta, F. P., & Boulton, D. W. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01314.x · Cited by 93
Self-citation
Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death
Shibusawa, R., Yamada, E., Okada, S., Nakajima, Y., Bastie, C. C., Maeshima, A., Kaira, K., & Yamada, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-46402-6 · Cited by 89
From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus
Bays, H. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802710422 · Cited by 83
The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes
He, Y., Haynes, W., Meyers, C. D., Amer, A., Zhang, Y., Mahling, P., Mendonza, A. E., Ma, S., Chutkow, W., & Bachman, E. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13654 · Cited by 81
Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
Washburn, W. N., & Poucher, S. M. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.774372 · Cited by 81
Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development
Gronda, E., Jessup, M. L., Iacoviello, M., Palazzuoli, A., & Claudio Napoli, A. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018889 · Cited by 81
Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
Johnston, R., Uthman, O. A., Cummins, E., Clar, C., Royle, P., Colquitt, J. L., Tan, B. K., Clegg, A. J., Shantikumar, S., Court, R. A., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21020 · Cited by 84

Authors: Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M.
Affiliations: Bristol-Myers Squibb (United States) (US)
Corresponding author: Pfister, M
ORCID: Pfister, M
Venue: Clinical Pharmacology & Therapeutics
Publisher: Wiley
Published: 2009-01-07
Volume: 85
Issue: 5
Pages: 513-519
ISSN: 0009-9236 (ISSN-L)
1532-6535
DOI: 10.1038/clpt.2008.250
OpenAlex: W2000047428
Cited by: 396
References: 20
Citations by year: 2026: 14 · 2025: 13 · 2024: 16 · 2023: 14 · 2022: 16 · 2021: 17 · 2020: 14 · 2019: 22 · 2018: 18 · 2017: 19 · 2016: 24 · 2015: 18 · 2014: 39 · 2013: 39 · 2012: 32
FWCI: 27.68
Type: journal article
Language: en
Open access: closed
Locations: Clinical Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords: dapagliflozin, SGLT2 inhibitors, type 2 diabetes, glycemic control, glycosuria, fasting serum glucose, oral glucose tolerance test, dose-dependent effects, urinary glucose excretion
MeSH terms: Sodium-Glucose Transporter 2 Inhibitors, Administration, Oral, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glucose Tolerance Test, Glucosides, Glycosuria, Humans, Hypoglycemic Agents, Male, Middle Aged, Time Factors, Sodium-Glucose Transporter 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks